Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

被引：0
|
作者：
Thehang Luu
Kyu-pyo Kim
Suzette Blanchard
Bean Anyang
Arti Hurria
Lixin Yang
Jan H. Beumer
George Somlo
Yun Yen
机构：
[1] City of Hope Medical Center,Department of Medical Oncology
[2] OncoGambit,Cancer Therapeutics Program
[3] LLC,Department of Oncology, Asan Medical Center
[4] University of Pittsburgh Cancer Institute,Department of Biostatistics
[5] University of Ulsan College of Medicine,Department of Molecular
[6] City of Hope,Department of Pharmaceutical Sciences
[7] City of Hope,Division of Hematology/Oncology, Department of Medicine
[8] University of Pittsburgh School of Pharmacy,Pharmacology, Beckman Research Institute
[9] University of Pittsburgh School of Medicine,Cancer Research and Drug Discovery Medical Technology College
[10] City of Hope,undefined
[11] Taipei Medical University,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 167卷
关键词：
Phase IB clinical trial; Ixabepilone; Vorinostat; Metastatic breast cancer; Histone deacetylation inhibitors (HDACIs);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：469 / 478
页数：9
相关论文
共 50 条
  • [1] Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer
    Luu, Thehang
    Kim, Kyu-pyo
    Blanchard, Suzette
    Anyang, Bean
    Hurria, Arti
    Yang, Lixin
    Beumer, Jan H.
    Somlo, George
    Yen, Yun
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 469 - 478
  • [2] Phase I trial of ixabepilone and vorinostat in metastatic breast cancer.
    Luu, Thehang H.
    Blanchard, Suzette
    Beumer, Jan Hendrik
    Anyang, Bean N.
    Somlo, George
    Mortimer, Joanne E.
    Hurria, Arti
    Yang, Lixin
    Yen, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Ixabepilone/epiribicin combination as therapy for metastatic breast cancer - a phase Ib study
    Roche, H.
    Zambetti, M.
    Dalenc, F.
    De Benedictis, E.
    Gladieff, L.
    Mudenda, B.
    Messina, M.
    Lainas, I.
    Gianni, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 267 - 268
  • [4] Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer
    Roche, H. H.
    Zambetti, M.
    Dalenc, F.
    Govi, S.
    Gladieff, L.
    Mudenda, B.
    Lainas, I.
    Iacono, L.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC)
    Schwartzberg, L. S.
    Tauer, K. W.
    Schnell, F. M.
    Hermann, R.
    Rubin, P.
    Christianson, D.
    Weinstein, P.
    Epperson, A.
    Walker, M.
    CANCER RESEARCH, 2012, 72
  • [6] A Phase II Trial of Vorinostat in Metastatic Breast Cancer (vol 14, pg 7138, 2008)
    Luu, T. H.
    Morgan, R. J.
    Leong, L.
    CLINICAL CANCER RESEARCH, 2009, 15 (01) : 416 - 416
  • [7] Phase II Trial of Ixabepilone Plus Carboplatin in Patients with Metastatic Breast Cancer: The ECLIPSE Study.
    Osborne, C.
    Challagalla, J. D.
    Fanning, S. R.
    Eisenbeis, C. F.
    Holmes, F. A.
    Monaghan, G. G.
    Neubauer, M. A.
    Rabe, A. C.
    Raja, V.
    Robbins, G. J.
    Taboada, C.
    Vukelja, S. J.
    Wilks, S. T.
    Wang, Y.
    Brown, J-A
    Asmar, L.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2011, 71
  • [8] Phase I/II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC)
    Schwartzberg, Lee S.
    Blakely, Laura J.
    Schnell, Frederick
    Christianson, David
    Andrews, Michael
    Johns, Amanda
    Walker, Mark
    CANCER RESEARCH, 2011, 71
  • [9] A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
    Luu, Thehang H.
    Morgan, Robert J.
    Leong, Lucille
    Lim, Dean
    McNamara, Mark
    Portnow, Jana
    Frankel, Paul
    Smith, David D.
    Doroshow, James H.
    Gandara, David R.
    Aparicio, Ana
    Somlo, George
    Wong, Carol
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 7138 - 7142
  • [10] Ixabepilone In Locally Advanced or Metastatic Breast Cancer
    Moen, Marit D.
    DRUGS, 2009, 69 (11) : 1471 - 1481
12345